Wedbush reduced its rating on Illumina (NASDAQ: ILMN ) from Outperform to Neutral and reiterated its $52 price target. Wedbush noted, "We have spoken with several typical sequencing customers recently that are either putting off or second guessing HiSeq purchases because of the attractive price point of